The effect of vasopressin on pulmonary vascular resistance in septic shock

Zusammenfassung der Studie

Intensive care patients with septic shock often require high doses of circulatory support medications (typically norepinephrine) to stabilize systemic blood pressure. As undesirable side effects, impairments in pulmonary circulation may occur (right heart problems, increased resistance in the pulmonary vessels). Vasopressin is another medication approved for the treatment of septic shock. Interestingly, there seem to be no receptors in the pulmonary circulation where vasopressin can act, unlike norepinephrine. Therefore, the aforementioned norepinephrine-associated problems may occur less frequently when vasopressin is administered simultaneously, allowing for a reduction in the norepinephrine dose. This prospective project will examine, according to a well-defined protocol, how pulmonary circulation changes with the use of vasopressin in patients with septic shock. We hypothesize that resistance in the pulmonary vessels does not increase or even decreases with the simultaneous use of vasopressin, which would be beneficial for right heart function.

(BASEC)

Untersuchte Intervention

The effect of vasopressin on resistance in the pulmonary vessels in patients with septic shock will be investigated.

(BASEC)

Untersuchte Krankheit(en)

Severely ill patients with septic shock, who are treated in the intensive care unit, will be studied.

(BASEC)

Sponsor

Prof. Dr. med. Sascha David Universitätsspital Zürich – Institut für Intensivmedizin Rämistrasse 100 CH-8091 Zurich

(BASEC)

Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)

Ethikkommission Zürich

(BASEC)

Datum der Bewilligung durch die Ethikkommission

10.12.2024

(BASEC)

Ergebnisse der Studie